Treat the draining lymph node before removing it
The first lymph node cancer reaches is also where the immune system learns to fight it. Injecting immunotherapy into that node before surgery, instead of removing it blindly, may work better.
Tumour-draining lymph nodes hold the stem-like precursor T cells that checkpoint blockade depends on, so removing or irradiating them may remove the substrate of response. Peritumoural or intranodal injection achieves high nodal exposure at a small fraction of the systemic dose, and small trials of peritumoural nivolumab in oral cancer and intratumoural ipilimumab in melanoma showed nodal immune activation.
- Metastasis is understood least and studied last · Metastasis causes about nine in ten cancer deaths but gets a small fraction of research money and almost no trials of its own.
- Cold tumours and the immunosuppressive microenvironment · Most tumours keep the immune system out or asleep, so immunotherapy helps only a minority.
- Toxicity and quality of life are undervalued · Trials measure how long people live, not how they live. Side-effects are under-reported and under-treated.
Pages like this
not linked directly; found by shared links- Key paperNADINA: two doses of ipilimumab plus nivolumab before surgery beat a year of nivolumab after surgery in stage III melanoma
Shares Christian Blank, John Haanen, Immune-related adverse events (irAEs), Ipilimumab.
- PairingNeoadjuvant immunotherapy → response-adapted adjuvant
Shares Major pathological response (MPR), Sentinel lymph node biopsy, Ipilimumab, Nivolumab.
- TrialNADINA
Shares Major pathological response (MPR), Christian Blank, Ipilimumab, Nivolumab.
- IdeaPredict immune side-effects before they happen and pre-empt them
Shares Immune-related adverse events (irAEs), Ipilimumab, Toxicity and quality of life are undervalued, Immune checkpoint inhibitors.
- Key paperCheckMate 067 at ten years: nivolumab plus ipilimumab produces long-term survival in half of patients with advanced melanoma
Shares John Haanen, Immune-related adverse events (irAEs), Ipilimumab, Nivolumab.
- TermImmune-related endocrinopathies (thyroiditis, hypophysitis)
Shares Immune-related adverse events (irAEs), Ipilimumab, Nivolumab, Immune checkpoint inhibitors.
- Key paperASCO 2021 guideline: how to recognise and manage the immune-related side effects of checkpoint inhibitors
Shares Immune-related adverse events (irAEs), Ipilimumab, Nivolumab, Toxicity and quality of life are undervalued.
- Key paperNICHE-2: a month of nivolumab and ipilimumab before surgery clears mismatch-repair-deficient colon cancer in most patients
Shares John Haanen, Immune-related adverse events (irAEs), Ipilimumab, Nivolumab.